Bristol Myers Squibb (NYSE: BMY) has announced the successful results of the pivotal Phase 3 KRYSTAL-12 study, which evaluated KRAZATI® (adagrasib) as a monotherapy for patients with previously treated locally…
Bristol Myers Squibb (NYSE: BMY) provided an update today following the preliminary analysis of findings from the first of two induction studies within the Phase 3 YELLOWSTONE clinical trial program,…
Bristol Myers Squibb (NYSE: BMY) has introduced a $1.8 million initiative aimed at promoting health equity by tackling social determinants of health (SDoH) in four countries with underserved patient populations:…
Bristol Myers Squibb (NYSE: BMY) announced today the unveiling of data at the American College of Cardiology (ACC) Annual Scientific Session & Expo, scheduled for April 6-8, 2024, in Atlanta,…
Roche, a leading healthcare company (SIX: RO, ROG; OTCQX: RHHBY), has announced today the approval by the U.S. Food and Drug Administration (FDA) for its cobas® Malaria test, designed for…
Merck, also known as MSD outside of the United States and Canada, has announced today that the European Commission (EC) has granted approval for KEYTRUDA, Merck’s anti-PD-1 therapy. This approval…
Merck, known as MSD outside of the United States and Canada, has announced that the U.S. Food and Drug Administration (FDA) has given approval for sotatercept-csrk, branded as WINREVAIR™ in…
AbbVie Inc. (NYSE: ABBV) (“AbbVie”) and Landos Biopharma, Inc. (NASDAQ: LABP) (“Landos”) have announced a definitive agreement today, wherein AbbVie will acquire Landos, a clinical stage biopharmaceutical company primarily focused…
Novo Nordisk and Cardior Pharmaceuticals have announced a significant acquisition deal, with Novo Nordisk set to acquire Cardior for up to 1.025 billion Euros. This includes an upfront payment along…
Novo Nordisk has announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has provided a positive opinion, recommending the marketing authorization for Awiqli® (the branded…
The “Global Covid-19 Diagnostic Market Forecast by Technology, Product, Channel and Country with Executive and Consultant Guides” report has been added to ResearchAndMarkets.com’s offering. Amidst signs of the pandemic easing, Covid-19 continues to reshape…
Gilead Sciences, Inc. (Nasdaq: GILD) has finalized its acquisition of CymaBay Therapeutics, Inc. (Nasdaq: CBAY) for an estimated total equity value of about $4.3 billion. This strategic move enhances Gilead’s…